Krystal Biotech (KRYS) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Vaxcyte (PCVX) over the past year, gaining 77.3% versus a gain of 59.9%. Over five years, KRYS leads with a +566.2% price change compared with +174.3% for PCVX. Vaxcyte is the larger company by market cap ($9.96 billion vs $9.61 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | PCVX |
|---|---|---|
| Share price | $324.57 | $66.96 |
| Market cap | $9.61B | $9.96B |
| 1-day change | -0.69% | +0.39% |
| YTD return | +31.65% | +45.12% |
| 1-year return | +77.34% | +59.92% |
| 5-year return | +566.19% | +174.31% |
| P/E ratio (TTM) | 40.67 | — |
| Forward P/E | 34.83 | — |
| EPS (TTM) | $7.98 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $389.13M | — |
| Revenue growth (YoY) | +33.94% | — |
| Net income (latest FY) | $204.83M | $-766.63M |
| Operating margin | 41.45% | — |
| Net margin | 52.64% | — |
| 52-week high | $382.54 | $90.75 |
| 52-week low | $179.19 | $39.87 |
| Distance from 52-week high | -15.15% | -26.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +20.81% | +65.59% |
| Average volume | 381.19K | 1.50M |
| Shares outstanding | 29.60M | 148.81M |
| Employees | 295 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed PCVX by 17.4 percentage points over the past year.
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
KRYS vs PCVX FAQ
Which is bigger, Krystal Biotech or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $9.96B compared with $9.61B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, KRYS or PCVX?
KRYS returned +77.34% over the past 12 months, compared with +59.92% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Krystal Biotech and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.